ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Caixin

Eli Lilly partners with Shanghai Junshi for COVID-19 cure

Deal empowers Chinese company to fast-track promising coronavirus therapies

The joint effort may allow the partnership to initiate clinical studies in the U.S. later this year, as the dramatic drop of COVID-19 patients in China makes trials there more difficult.   © Reuters

U.S. pharmaceutical Eli Lilly is partnering with Chinese drugmaker Shanghai Junshi Biosciences to develop new antibody therapies for COVID-19, the disease that has sickened 3.6 million people worldwide.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more